ReviewClinical medicine (London, England)2017
Hypercalcaemia - presentation and management .
Review in Clinical medicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review.Archives of endocrinology and metabolism · 2024Pooled it
- Evaluating the Whole Blood Survival Advantage: How Citrate and Calcium Levels Drive Mortality in a Translational Swine Model of Polytrauma.Journal of the American College of Emergency Physicians open · 2026Article
- Evaluating the preoperative diagnostic value ofJournal of applied clinical medical physics · 2026Article
- Parathyroid surgery for hypercalcaemic crisis in primary hyperparathyroidism-a retrospective study.Gland surgery · 2026Article
- Postparathyroidectomy calciphylaxis in a patient with primary hyperparathyroidism: a rare complication.JCEM case reports · 2026Article
- Primary hyperparathyroidism-associated pancreatitis: poor prognosis, distinct serum calcium trajectories, and proactive therapeutic implications.Gastroenterology report · 2026Article
- Safety and efficacy of ultrasound-guided microwave ablation in patients with primary hyperparathyroidism: a single-center retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management.Kidney medicine · 2026Review
- Salivary proteomics of patients with type 2 diabetes identify potential biomarkers for diabetes and highlight significant role of immune response.Clinical and experimental medicine · 2026Article
- Intramuscular synthol injections cause hypercalcemia in long-term observation: a case report study.BMC nephrology · 2025Article
- Hypercalcemia with the Oral Administration of Active Vitamin D3 and Chinese Herbal Medicine.Internal medicine (Tokyo, Japan) · 2025Article
- Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia.Head & neck · 2025Observational
- Recurrent Brown Tumors as a Presenting Complaint of Primary Hyperparathyroidism: A Case Report.Clinical case reports · 2025Article
- Extreme hypercalcemia secondary to parathyroid adenoma obscured by excessive coffee consumption and premature ventricular complexes.Journal of general and family medicine · 2025Article
- Hypercalcemia and Acute Kidney Injury Associated with Disseminated Paracoccidioidomycosis.The American journal of tropical medicine and hygiene · 2025Article
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
- Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1.The Journal of clinical endocrinology and metabolism · 2024Article
- Intentional vomiting as a rare cause of hypercalcemia and consequent acute renal failure: a case report.Frontiers in medicine · 2024Article
- Gastrointestinal stromal tumour-induced hypercalcaemia.BMJ case reports · 2023Article
- Neurorescuing effect of Cinacalcet against hypercalcemia-induced nerve injury in chronic kidney disease via TRAF2/cIAP1/KLF2/SERPINA3 signal axis.Cell biology and toxicology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercalcaemia is a common disorder normally caused by primary hyperparathyroidism (PHPT) or malignancy. A proportion of cases present as an emergency, which carries a significant mortality. Emergency management of hypercalcaemia is based on intravenous rehydration with normal saline but when this is inadequate, bisphosphonate therapy is used; more recently the novel anti-resorbtive agent denosumab has been shown to have a useful role in treatment. It is estimated that up to 10% of all cases of PHPT presenting under the age of 45 years have an underlying genetic predisposition; nine potentially causative genes are now recognised and may be screened in routine clinical practice. Although parathyroidectomy is the only curative treatment for PHPT, this is indicated in a minority of cases. Many cases can be adequately managed conservatively and guidance from the 4th international workshop on the management of asymptomatic PHPT has recently been updated in a consensus statement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.